Global Idiopathic Pulmonary Fibrosis (IPF) Competitor Landscape 2018: Analysis of Current & Potential Future Product Positioning

Dublin, Feb. 05, 2019 (GLOBE NEWSWIRE) — The “Competitor Landscape: Idiopathic Pulmonary Fibrosis (IPF)” report has been added to’s offering.

“Competitor Landscape: Idiopathic Pulmonary Fibrosis (IPF)”, briefing contains evaluations of ongoing development activities within the Idiopathic Pulmonary Fibrosis (IPF) disease market, together with analysis of current & potential future product positioning.

Key Highlights of the report

  • Development of PBI-4050 is expected to be delayed, due to Prometic’s need for financing, potentially losing its first mover position vs. FibroGen & Galapagos, which have already announced the timeline for their respective Phase III trials.
  • FibroGen’s pamrevlumab is expected to be the second novel candidate to achieve approval in IPF (pending successful Phase III trials), and its approval could be accelerated due to the fast track designation in the US.
  • Promedior’s PRM-151 is expected to be the third novel therapy to be approved in IPF, however, Promedior did not provide a clear timeline for Phase III trial initiation, suggesting a potential delay in its development.

Key Summary

Landscape Updates

  • Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher.
  • Timeline forecasts for each approved product’s lifecycle management initiatives.

Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status.

Approved Product Landscape: An overview of approved candidates, containing snapshots of current development status


  • Current Early Stage IPF Pipeline Watch List’ and discontinued/inactive candidate list.
  • Timeline Assumptions, including standard & drug-specific assumptions.
  • Glossary and notes on landscape inclusion criteria.


  • The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (
  • Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher – these are outlined in the report Appendix
  • Forecasts are presented in pipeline forecast figures & detailed tables
  • Market Entry’ & Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided.

Key Topics Covered:

  1. Introduction to Sociable Pharma’s IPF Competitor Landscape’
  2. Executive Summary
  3. Key Events & Landscape Updates
  4. Landscape Updates
  5. Pipeline Candidate Order of Entry
  6. Approved Product Lifecycle Development
  7. Pipeline Landscape
  8. Pipeline Summary
  9. Approved Product Development Landscape
  10. Approved Product Summary
  11. Appendix

Companies Mentioned

  • AdAlta
  • Afferent Pharmaceuticals/Merck
  • Analyn
  • Ark Biosciences
  • Biogen
  • BMS
  • Boehringer Ingelheim
  • Bridge Biotherapeutics
  • Celgene
  • FibroGen
  • Galapagos
  • Galecto Biotech
  • Genkyotex
  • Global Blood Therapeutics
  • GSK
  • Guangdong Zhongsheng Pharma
  • HEC Pharm
  • Kadmon Corporation
  • MediciNova
  • Metagone Biotech
  • Moerae Matrix
  • Nitto Biopharma
  • Novartis
  • Patara Pharma
  • Pharmaxis
  • Promedior
  • Prometic
  • Reviva Pharma
  • Roche
  • Roivant Sciences
  • Samumed
  • Sanofi
  • Synairgen
  • United therapeutics
  • Vicore Pharma
  • X-Rx
  • ZAI Lab

For more information about this report visit

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

         Laura Wood, Senior Press Manager
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
Related Topics: Respiratory Drugs, Pulmonary Medicine